{"id":383860,"date":"2020-11-18T08:03:19","date_gmt":"2020-11-18T13:03:19","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=383860"},"modified":"2020-11-18T08:03:19","modified_gmt":"2020-11-18T13:03:19","slug":"fortress-biotech-ranked-in-deloittes-technology-fast-500-for-the-second-year-in-a-row","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/fortress-biotech-ranked-in-deloittes-technology-fast-500-for-the-second-year-in-a-row\/","title":{"rendered":"Fortress Biotech Ranked in Deloitte\u2019s Technology Fast 500\u2122 for the Second Year in a Row"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">NEW YORK, Nov.  18, 2020  (GLOBE NEWSWIRE) &#8212; Fortress Biotech, Inc. (NASDAQ: FBIO) (\u201cFortress\u201d), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that it ranked number 135 in Deloitte\u2019s 2020 Technology Fast 500\u2122, an annual ranking of the fastest-growing North American companies in the technology, media, telecommunications, life sciences and energy tech sectors. Fortress\u2019 874 percent revenue growth based on the increase in net product sales from 2016 to 2019 secured its spot in the rankings.<\/p>\n<p align=\"justify\">\u201cWe are thrilled to be recognized among an elite group of 500 companies in Deloitte\u2019s Technology Fast 500\u2122 for the second year in a row. We are proud of our rapid revenue growth, as generating value for our shareholders is always a top priority,\u201d said Lindsay A. Rosenwald, M.D., Fortress\u2019 Chairman, President and Chief Executive Officer. \u201cOur business strategy allows us to acquire and develop a broad array of new marketed products and product candidates with significant commercial and clinical potential. Through our approach, we have established a growing portfolio of five marketed products and over 25 development-stage programs that we believe will provide our company and its shareholders with a diversified long-term revenue stream.\u201d<\/p>\n<p align=\"justify\">Now in its 26<sup>th<\/sup> year, the Technology Fast 500 selects companies based on percentage fiscal year revenue growth over a three-year period. Overall, the 2020 Technology Fast 500 companies achieved revenue growth ranging from 175 percent to 106,508 percent from 2016 to 2019, with a median growth rate of 450 percent. For more information about the Technology Fast 500, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uF5PDbZXL8QpWoLwpS1veCIddrpmeaOVF3AxZEKAy3o9__v-8PR-zEBznOJXPbOtRZooxnaSK4ApBZNdR-ycew==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.fast500.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About Fortress Biotech <\/strong><br \/>\n        <br \/>Fortress Biotech, Inc. (\u201cFortress\u201d) is an innovative biopharmaceutical company that was ranked in Deloitte\u2019s 2019 and 2020 Technology Fast 500\u2122, annual rankings of the fastest-growing North American companies in the technology, media, telecommunications, life sciences and energy tech sectors, based on percentages of fiscal year revenue growth over three-year periods. Fortress is focused on acquiring, developing and commercializing high-potential marketed and development-stage drugs and drug candidates. The company has five marketed prescription pharmaceutical products and over 25 programs in development at Fortress, at its majority-owned and majority-controlled partners and at partners it founded and in which it holds significant minority ownership positions. Such product candidates span six large-market areas, including oncology, rare diseases and gene therapy, which allow it to create value for shareholders. Fortress advances its diversified pipeline through a streamlined operating structure that fosters efficient drug development. The Fortress model is driven by a world-class business development team that is focused on leveraging its significant biopharmaceutical industry expertise to further expand the company\u2019s portfolio of product opportunities. Fortress has established partnerships with some of the world\u2019s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including Alexion Pharmaceuticals, Inc., AstraZeneca, City of Hope, Fred Hutchinson Cancer Research Center, InvaGen Pharmaceuticals Inc. (a subsidiary of Cipla Limited), St. Jude Children\u2019s Research Hospital and Nationwide Children\u2019s Hospital. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=dlPP9drZXgkUihITulpl1zEb6lQ2KcUvERWFIwMwhct4m34EXpvpvp0kQ0NeiA3QiFqyoaL0wSdSOoizkBMWVTTKKgvTA8N1-l1-XQfHV9g=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.fortressbiotech.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release may contain \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. As used below and throughout this press release, the words \u201cwe\u201d, \u201cus\u201d and \u201cour\u201d may refer to Fortress individually or together with one or more partner companies, as dictated by context. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management\u2019s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; risks relating to the timing of starting and completing clinical trials; our dependence on third-party suppliers; risks relating to the COVID-19 outbreak and its potential impact on our employees\u2019 and consultants\u2019 ability to complete work in a timely manner and on our ability to obtain additional financing on favorable terms or at all; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The information contained herein is intended to be reviewed in its totality, and any stipulations, conditions or provisos that apply to a given piece of information in one part of this press release should be read as applying <em>mutatis mutandis<\/em> to every other instance of such information appearing herein.<\/p>\n<p>\n        <strong>Company Contacts:<\/strong><br \/>\n        <br \/>Jaclyn Jaffe and William Begien<br \/>Fortress Biotech, Inc.<br \/>(781) 652-4500<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=39IGqPW_hJZjZrZz8876Htn5eS9nThz2m2Ggul0PwffhVHccjygcT0CgO9RF73cVECZYYuGTJsqgfzrlcy4KZGLWrPoO-yajZkxpHvxDCwQ=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">ir@fortressbiotech.com<\/a><\/p>\n<p>\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>Daniel Ferry<br \/>LifeSci Advisors, LLC<br \/>(617) 430-7576<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ATUDwmoeqyK4XcNaVb3n86IN0ru4ee_IJhC5K569BlPWF1vutUhl3ezDUKmCsYg5pJX0PWBdKOtviIxW_yeg8iNzwne2gp5O_Hc-uO6qZeHxK9LsDE2O_A-9DybV7ZJi\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">daniel@lifesciadvisors.com<\/a><\/p>\n<p>\n        <strong>Media Relations Contact:<\/strong><br \/>\n        <br \/>Tony Plohoros<br \/>6 Degrees<br \/>(908) 591-2839<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KxyrPJGdZq_ZTx5nPHoG1_toF1RlKjG3la9UDpndSFesOcbUjYlE__uF2uey9WpBqivl9bhVB5efV9x81172FPCxcA27tHpEuHHjBvlIyQM=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>tplohoros@6degreespr.com<\/u><\/a>\u00a0\u00a0<\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODE0OSMzODMyODkyIzIwMjY1NTI=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/a86300c7-9c4c-4d91-9120-7d1f70268a6f\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) &#8212; Fortress Biotech, Inc. (NASDAQ: FBIO) (\u201cFortress\u201d), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that it ranked number 135 in Deloitte\u2019s 2020 Technology Fast 500\u2122, an annual ranking of the fastest-growing North American companies in the technology, media, telecommunications, life sciences and energy tech sectors. Fortress\u2019 874 percent revenue growth based on the increase in net product sales from 2016 to 2019 secured its spot in the rankings. \u201cWe are thrilled to be recognized among an elite group of 500 companies in Deloitte\u2019s Technology Fast 500\u2122 for the second year in a row. We are proud of our rapid &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/fortress-biotech-ranked-in-deloittes-technology-fast-500-for-the-second-year-in-a-row\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Fortress Biotech Ranked in Deloitte\u2019s Technology Fast 500\u2122 for the Second Year in a Row&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-383860","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Fortress Biotech Ranked in Deloitte\u2019s Technology Fast 500\u2122 for the Second Year in a Row - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/fortress-biotech-ranked-in-deloittes-technology-fast-500-for-the-second-year-in-a-row\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Fortress Biotech Ranked in Deloitte\u2019s Technology Fast 500\u2122 for the Second Year in a Row - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) &#8212; Fortress Biotech, Inc. (NASDAQ: FBIO) (\u201cFortress\u201d), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that it ranked number 135 in Deloitte\u2019s 2020 Technology Fast 500\u2122, an annual ranking of the fastest-growing North American companies in the technology, media, telecommunications, life sciences and energy tech sectors. Fortress\u2019 874 percent revenue growth based on the increase in net product sales from 2016 to 2019 secured its spot in the rankings. \u201cWe are thrilled to be recognized among an elite group of 500 companies in Deloitte\u2019s Technology Fast 500\u2122 for the second year in a row. We are proud of our rapid &hellip; Continue reading &quot;Fortress Biotech Ranked in Deloitte\u2019s Technology Fast 500\u2122 for the Second Year in a Row&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/fortress-biotech-ranked-in-deloittes-technology-fast-500-for-the-second-year-in-a-row\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-18T13:03:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODE0OSMzODMyODkyIzIwMjY1NTI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fortress-biotech-ranked-in-deloittes-technology-fast-500-for-the-second-year-in-a-row\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fortress-biotech-ranked-in-deloittes-technology-fast-500-for-the-second-year-in-a-row\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Fortress Biotech Ranked in Deloitte\u2019s Technology Fast 500\u2122 for the Second Year in a Row\",\"datePublished\":\"2020-11-18T13:03:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fortress-biotech-ranked-in-deloittes-technology-fast-500-for-the-second-year-in-a-row\\\/\"},\"wordCount\":915,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fortress-biotech-ranked-in-deloittes-technology-fast-500-for-the-second-year-in-a-row\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4ODE0OSMzODMyODkyIzIwMjY1NTI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fortress-biotech-ranked-in-deloittes-technology-fast-500-for-the-second-year-in-a-row\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fortress-biotech-ranked-in-deloittes-technology-fast-500-for-the-second-year-in-a-row\\\/\",\"name\":\"Fortress Biotech Ranked in Deloitte\u2019s Technology Fast 500\u2122 for the Second Year in a Row - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fortress-biotech-ranked-in-deloittes-technology-fast-500-for-the-second-year-in-a-row\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fortress-biotech-ranked-in-deloittes-technology-fast-500-for-the-second-year-in-a-row\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4ODE0OSMzODMyODkyIzIwMjY1NTI=\",\"datePublished\":\"2020-11-18T13:03:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fortress-biotech-ranked-in-deloittes-technology-fast-500-for-the-second-year-in-a-row\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fortress-biotech-ranked-in-deloittes-technology-fast-500-for-the-second-year-in-a-row\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fortress-biotech-ranked-in-deloittes-technology-fast-500-for-the-second-year-in-a-row\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4ODE0OSMzODMyODkyIzIwMjY1NTI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4ODE0OSMzODMyODkyIzIwMjY1NTI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/fortress-biotech-ranked-in-deloittes-technology-fast-500-for-the-second-year-in-a-row\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fortress Biotech Ranked in Deloitte\u2019s Technology Fast 500\u2122 for the Second Year in a Row\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Fortress Biotech Ranked in Deloitte\u2019s Technology Fast 500\u2122 for the Second Year in a Row - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/fortress-biotech-ranked-in-deloittes-technology-fast-500-for-the-second-year-in-a-row\/","og_locale":"en_US","og_type":"article","og_title":"Fortress Biotech Ranked in Deloitte\u2019s Technology Fast 500\u2122 for the Second Year in a Row - Market Newsdesk","og_description":"NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) &#8212; Fortress Biotech, Inc. (NASDAQ: FBIO) (\u201cFortress\u201d), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that it ranked number 135 in Deloitte\u2019s 2020 Technology Fast 500\u2122, an annual ranking of the fastest-growing North American companies in the technology, media, telecommunications, life sciences and energy tech sectors. Fortress\u2019 874 percent revenue growth based on the increase in net product sales from 2016 to 2019 secured its spot in the rankings. \u201cWe are thrilled to be recognized among an elite group of 500 companies in Deloitte\u2019s Technology Fast 500\u2122 for the second year in a row. We are proud of our rapid &hellip; Continue reading \"Fortress Biotech Ranked in Deloitte\u2019s Technology Fast 500\u2122 for the Second Year in a Row\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/fortress-biotech-ranked-in-deloittes-technology-fast-500-for-the-second-year-in-a-row\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-18T13:03:19+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODE0OSMzODMyODkyIzIwMjY1NTI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fortress-biotech-ranked-in-deloittes-technology-fast-500-for-the-second-year-in-a-row\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fortress-biotech-ranked-in-deloittes-technology-fast-500-for-the-second-year-in-a-row\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Fortress Biotech Ranked in Deloitte\u2019s Technology Fast 500\u2122 for the Second Year in a Row","datePublished":"2020-11-18T13:03:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fortress-biotech-ranked-in-deloittes-technology-fast-500-for-the-second-year-in-a-row\/"},"wordCount":915,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fortress-biotech-ranked-in-deloittes-technology-fast-500-for-the-second-year-in-a-row\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODE0OSMzODMyODkyIzIwMjY1NTI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fortress-biotech-ranked-in-deloittes-technology-fast-500-for-the-second-year-in-a-row\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/fortress-biotech-ranked-in-deloittes-technology-fast-500-for-the-second-year-in-a-row\/","name":"Fortress Biotech Ranked in Deloitte\u2019s Technology Fast 500\u2122 for the Second Year in a Row - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fortress-biotech-ranked-in-deloittes-technology-fast-500-for-the-second-year-in-a-row\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fortress-biotech-ranked-in-deloittes-technology-fast-500-for-the-second-year-in-a-row\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODE0OSMzODMyODkyIzIwMjY1NTI=","datePublished":"2020-11-18T13:03:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fortress-biotech-ranked-in-deloittes-technology-fast-500-for-the-second-year-in-a-row\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/fortress-biotech-ranked-in-deloittes-technology-fast-500-for-the-second-year-in-a-row\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fortress-biotech-ranked-in-deloittes-technology-fast-500-for-the-second-year-in-a-row\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODE0OSMzODMyODkyIzIwMjY1NTI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4ODE0OSMzODMyODkyIzIwMjY1NTI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/fortress-biotech-ranked-in-deloittes-technology-fast-500-for-the-second-year-in-a-row\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Fortress Biotech Ranked in Deloitte\u2019s Technology Fast 500\u2122 for the Second Year in a Row"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/383860","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=383860"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/383860\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=383860"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=383860"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=383860"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}